DVAX (Dynavax) Kacepetan wutah bathi saben saham ing taun lumaku

Lambang korporat lan logo dynavax.com (DVAX)

Dynavax Technologies (DVAX) vaccine production relies on sterile robotic lines supplemented by the work of scientists. The percentage deviation of EPS from last year demonstrates profit dynamics, where the 0.00 level reflects the current magnitude. Profit growth is based on the expansion of Heplisav-B within the global immunization sector and a steady increase in demand from corporate healthcare programs.

DVAX (Dynavax Technologies) riwayat Wutah bathi ing taun lumaku saka 04.07.2022 nganti 21.02.2026

Rincian analitis lan laporan data perusahaan Dynavax Corp (DVAX)

- rega saham lan konsensus proyeksi valuasi:
Pambiji fundamental:Dynavax Technologies
Produk mawa merek Dynavax Technologies Corp

Dynavax Technologies margins are driven by the market expansion of the Heplisav-B vaccine and royalty payments for the CpG 1018 adjuvant. The year-over-year EPS growth rate reflects the change in net income per share relative to the same period last year, allowing investors to assess operational efficiency and the impact of commercial sales on the company's final market capitalization.